Track Boston Scientific Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Boston Scientific Corporation BSX · Stock Open Boston Scientific Corporation in new tab

51.43 USD
Add to portfolio
P/E
20.72
EPS
2.47
P/B
2.97
ROE
15.34
Beta
0.57
Target Price
62.69 USD
Boston Scientific Corporation logo

Boston Scientific Corporation

🧾 Earnings Recap – Q2 2026

Boston Scientific's shares were essentially unchanged (-0.1%) as the quarter showed steady organic sales growth and solid margins, but the market digested cautious guidance revisions driven by softness in WATCHMAN and electrophysiology (EP) segments.

  • Q2 organic revenue grew 7%, driven by Interventional Cardiology, Endoscopy, and Neuromodulation, within prior full-year guidance range.
  • Adjusted EPS of $0.86 rose 15%, aided by favorable tax outcomes, and operating margin was healthy at 28.4%.
  • Guidance trimmed: full-year organic growth now expected at 5%-6%, below previous midpoint; adjusted EPS growth moderation reflected in narrowed $3.28-$3.32 range.
  • Key headwinds in WATCHMAN (clinical evidence impacting referrals) and EP (unexpected share loss in U.S.) pressured outlook; these segments weigh on near-term growth.
  • Restructuring plan announced to deliver $500 million in run-rate savings by 2029, aiming to offset pressures and underpin improved growth in 2028 and beyond.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateOct. 28, 2026
P/E20.72
EPS2.47
Book Value17.23
Price to Book2.97
Debt/Equity50.15
% Insiders0.248%
Growth
Revenue Growth0.08%
Earnings Growth0.15%
Estimates
Forward P/E14.89
Forward EPS3.44
Target Mean Price62.69

DCF Valuation

Tweak assumptions to recompute fair value for Boston Scientific Corporation (BSX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Boston Scientific Corporation Logo Boston Scientific Corporation Analysis (BSX)

Official Website Stock

Is Boston Scientific Corporation a good investment? Boston Scientific Corporation (BSX) is currently trading at 51.43 USD. Market analysts have a consensus price target of 62.69 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 20.72. This valuation is generally in line with the broader market.

Earnings Schedule: Boston Scientific Corporation is expected to release its next earnings report on Oct. 28, 2026. The market consensus estimate for Forward EPS is 3.44.

Investor FAQ

Does Boston Scientific Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Boston Scientific Corporation?

Boston Scientific Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Oct. 28, 2026. The company currently has a trailing EPS of 2.47.

Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Exchange Ticker
BSX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 1, 1998 2.000000
Nov. 6, 2003 2.000000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion